Jonas Oldgren

Asundexian versus Apixaban in Patients with Atrial Fibrillation

Piccini, Jonathan P; Patel, Manesh R; Steffel, Jan; Ferdinand, Keith et al.

Ingår i New England Journal of Medicine, s. 23-32, 2025

• DOI för Asundexian versus Apixaban in Patients with Atrial Fibrillation

Biomarker-Based Model for Prediction of Ischemic Stroke in Patients With Atrial Fibrillation

Wallentin, Lars; Lindbäck, Johan; Hijazi, Ziad; Oldgren, Jonas et al.

Ingår i Journal of the American College of Cardiology, 2025

• DOI för Biomarker-Based Model for Prediction of Ischemic Stroke in Patients With Atrial Fibrillation

Large simple randomized controlled trials – from drugs to medical devices: lessons from recent experience

Buccheri, Sergio; James, Stefan; Mafham, Marion; Landray, Martin et al.

Ingår i Trials, 2025

• DOI för Large simple randomized controlled trials – from drugs to medical devices: lessons from recent experience
• Ladda ner fulltext (pdf) av Large simple randomized controlled trials – from drugs to medical devices: lessons from recent experience

Neuroglial Biomarkers for Risk Assessment of Ischemic Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation Not Receiving Oral Anticoagulation

Aulin, Julia; Sjölin, Karl; Lindbäck, Johan; Benz, Alexander P. et al.

Ingår i Journal of the American Heart Association, 2025

• DOI för Neuroglial Biomarkers for Risk Assessment of Ischemic Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation Not Receiving Oral Anticoagulation
• Ladda ner fulltext (pdf) av Neuroglial Biomarkers for Risk Assessment of Ischemic Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation Not Receiving Oral Anticoagulation

The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF): Rationale and design

Lund, Lars H; James, Stefan; DeVore, Adam D; Anstrom, Kevin J et al.

Ingår i European Journal of Heart Failure, s. 2453-2463, 2024

• DOI för The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF): Rationale and design
• Ladda ner fulltext (pdf) av The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF): Rationale and design

Asundexian versus Apixaban in Patients with Atrial Fibrillation

Piccini, Jonathan P; Patel, Manesh R; Steffel, Jan; Ferdinand, Keith et al.

Ingår i New England Journal of Medicine, s. 23-32, 2025

• DOI för Asundexian versus Apixaban in Patients with Atrial Fibrillation

Biomarker-Based Model for Prediction of Ischemic Stroke in Patients With Atrial Fibrillation

Wallentin, Lars; Lindbäck, Johan; Hijazi, Ziad; Oldgren, Jonas et al.

Ingår i Journal of the American College of Cardiology, 2025

• DOI för Biomarker-Based Model for Prediction of Ischemic Stroke in Patients With Atrial Fibrillation

Neuroglial Biomarkers for Risk Assessment of Ischemic Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation Not Receiving Oral Anticoagulation

Aulin, Julia; Sjölin, Karl; Lindbäck, Johan; Benz, Alexander P. et al.

Ingår i Journal of the American Heart Association, 2025

• DOI för Neuroglial Biomarkers for Risk Assessment of Ischemic Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation Not Receiving Oral Anticoagulation
• Ladda ner fulltext (pdf) av Neuroglial Biomarkers for Risk Assessment of Ischemic Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation Not Receiving Oral Anticoagulation

The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF): Rationale and design

Lund, Lars H; James, Stefan; DeVore, Adam D; Anstrom, Kevin J et al.

Ingår i European Journal of Heart Failure, s. 2453-2463, 2024

• DOI för The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF): Rationale and design
• Ladda ner fulltext (pdf) av The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF): Rationale and design

Neurofilament Light Chain and Risk of Stroke in Patients With Atrial Fibrillation

Aulin, Julia; Sjölin, Karl; Lindbäck, Johan; Benz, Alexander P et al.

Ingår i Circulation, s. 1090-1100, 2024

• DOI för Neurofilament Light Chain and Risk of Stroke in Patients With Atrial Fibrillation

SGLT2 inhibitors for patients with type 2 diabetes mellitus after myocardial infarction: a nationwide observation registry study from SWEDEHEART

Rosén, Hans Christian; Mohammad, Moman A.; Jernberg, Tomas; James, Stefan et al.

Ingår i The Lancet Regional Health, 2024

• DOI för SGLT2 inhibitors for patients with type 2 diabetes mellitus after myocardial infarction: a nationwide observation registry study from SWEDEHEART
• Ladda ner fulltext (pdf) av SGLT2 inhibitors for patients with type 2 diabetes mellitus after myocardial infarction: a nationwide observation registry study from SWEDEHEART

Dapagliflozin in patients with myocardial infarction without diabetes or prior heart failure

James, Stefan; Storey, Robert F.; Oldgren, Jonas

Ingår i European Heart Journal - Cardiovascular Pharmacotherapy, s. 91-92, 2024

• DOI för Dapagliflozin in patients with myocardial infarction without diabetes or prior heart failure

Rationale and design of INFINITY-SWEDEHEART: A registry-based randomized clinical trial comparing clinical outcomes of the sirolimus-eluting DynamX bioadaptor to the zotarolimus-eluting Resolute Onyx stent

Erlinge, David; Andersson, Jonas; Froebert, Ole; Toernerud, Mattias et al.

Ingår i American Heart Journal, s. 1-10, 2024

• DOI för Rationale and design of INFINITY-SWEDEHEART: A registry-based randomized clinical trial comparing clinical outcomes of the sirolimus-eluting DynamX bioadaptor to the zotarolimus-eluting Resolute Onyx stent
• Ladda ner fulltext (pdf) av Rationale and design of INFINITY-SWEDEHEART: A registry-based randomized clinical trial comparing clinical outcomes of the sirolimus-eluting DynamX bioadaptor to the zotarolimus-eluting Resolute Onyx stent

Repeated Measurement of the Novel Atrial Biomarker BMP10 (Bone Morphogenetic Protein 10) Refines Risk Stratification in Anticoagulated Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial

Gkarmiris, Konstantinos I.; Lindbäck, Johan; Alexander, John H.; Granger, Christopher B. et al.

Ingår i Journal of the American Heart Association, 2024

• DOI för Repeated Measurement of the Novel Atrial Biomarker BMP10 (Bone Morphogenetic Protein 10) Refines Risk Stratification in Anticoagulated Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial
• Ladda ner fulltext (pdf) av Repeated Measurement of the Novel Atrial Biomarker BMP10 (Bone Morphogenetic Protein 10) Refines Risk Stratification in Anticoagulated Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial

Emergency department visit for atrial fibrillation: sex differences in treatment and outcomes in the Global RE-LY AF Registry

Johnson, Linda S.; Jiang, Yuxuan; Luu, Judy; Van Gelder, Isabelle C. et al.

Ingår i European Heart Journal, s. 2336-2340, 2024

• DOI för Emergency department visit for atrial fibrillation: sex differences in treatment and outcomes in the Global RE-LY AF Registry
• Ladda ner fulltext (pdf) av Emergency department visit for atrial fibrillation: sex differences in treatment and outcomes in the Global RE-LY AF Registry

Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden (INFINITY-SWEDEHEART): a single-blind, non-inferiority, registry-based, randomised controlled trial

Erlinge, David; Andersson, Jonas; Fröbert, Ole; Törnerud, Mattias et al.

Ingår i The Lancet, s. 1750-1759, 2024

• DOI för Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden (INFINITY-SWEDEHEART): a single-blind, non-inferiority, registry-based, randomised controlled trial

Sex differences in prevalence and characteristics of imaging-detected atherosclerosis: a population-based study

Swahn, Eva; Sederholm Lawesson, Sofia; Alfredsson, Joakim; Fredrikson, Mats et al.

Ingår i European Heart Journal Cardiovascular Imaging, s. 1663-1672, 2024

• DOI för Sex differences in prevalence and characteristics of imaging-detected atherosclerosis: a population-based study
• Ladda ner fulltext (pdf) av Sex differences in prevalence and characteristics of imaging-detected atherosclerosis: a population-based study

Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure.

James, Stefan; Erlinge, David; Storey, Robert F; McGuire, Darren K et al.

Ingår i NEJM evidence, 2024

• DOI för Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure.

SGLT2 Inhibitor Dapagliflozin Increases Skeletal Muscle and Brain Fatty Acid Uptake in Individuals With Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled Positron Emission Tomography Study

Latva-Rasku, Aino; Rebelos, Eleni; Tuisku, Jouni; Aarnio, Richard et al.

Ingår i Diabetes Care, 2024

• DOI för SGLT2 Inhibitor Dapagliflozin Increases Skeletal Muscle and Brain Fatty Acid Uptake in Individuals With Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled Positron Emission Tomography Study

Patients' experiences of clinical trial participation involving a product remotely assessing study drug adherence

Henriksson, Catrin; Olsson, Anneli; Andersen, Kasper; Arefalk, Gabriel et al.

Ingår i Contemporary Clinical Trials Communications, 2024

• DOI för Patients' experiences of clinical trial participation involving a product remotely assessing study drug adherence
• Ladda ner fulltext (pdf) av Patients' experiences of clinical trial participation involving a product remotely assessing study drug adherence

Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET/EHRA consensus conference

Schnabel, Renate B; Marinelli, Elena Andreassi; Arbelo, Elena; Boriani, Giuseppe et al.

Ingår i Europace, s. 6-27, 2023

• DOI för Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET/EHRA consensus conference
• Ladda ner fulltext (pdf) av Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET/EHRA consensus conference

Data standards for atrial fibrillation/flutter and catheter ablation: The European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart)

Batra, Gorav; Aktaa, Suleman; Camm, A. John; Costa, Francisco et al.

Ingår i European Heart Journal - Quality of Care and Clinical Outcomes, s. 609-620, 2023

• DOI för Data standards for atrial fibrillation/flutter and catheter ablation: The European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart)
• Ladda ner fulltext (pdf) av Data standards for atrial fibrillation/flutter and catheter ablation: The European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart)

Rationale and design of the DAPA-MI trial: Dapagliflozin in patients without diabetes mellitus with acute myocardial infarction

James, Stefan; Erlinge, David; Storey, Robert F.; Mcguire, Darren K. et al.

Ingår i American Heart Journal, s. 188-197, 2023

• DOI för Rationale and design of the DAPA-MI trial: Dapagliflozin in patients without diabetes mellitus with acute myocardial infarction
• Ladda ner fulltext (pdf) av Rationale and design of the DAPA-MI trial: Dapagliflozin in patients without diabetes mellitus with acute myocardial infarction

Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC-AF risk scores

Hijazi, Ziad; Lindbäck, Johan; Oldgren, Jonas; Benz, Alexander P. et al.

Ingår i American Heart Journal, s. 55-63, 2023

• DOI för Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC-AF risk scores
• Ladda ner fulltext (pdf) av Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC-AF risk scores

Plasma angiopoietin-2 and its association with heart failure in patients with atrial fibrillation

Benz, Alexander P.; Hijazi, Ziad; Lindbäck, Johan; Connolly, Stuart J. et al.

Ingår i Europace, 2023

• DOI för Plasma angiopoietin-2 and its association with heart failure in patients with atrial fibrillation
• Ladda ner fulltext (pdf) av Plasma angiopoietin-2 and its association with heart failure in patients with atrial fibrillation

Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI

Costa, Francesco; Valgimigli, Marco; Steg, Philippe Gabriel; Bhatt, Deepak L et al.

Ingår i European Heart Journal - Cardiovascular Pharmacotherapy, s. 216-226, 2022

• DOI för Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI

SGLT2 inhibition reduces myocardial oxygen consumption

Søndergaard, Esben; Lauritzen, Esben S; Lauritsen, Katrine M; Åkerblom, Axel et al.

Ingår i Metabolism Open, 2022

• DOI för SGLT2 inhibition reduces myocardial oxygen consumption
• Ladda ner fulltext (pdf) av SGLT2 inhibition reduces myocardial oxygen consumption

Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study

Oldgren, Jonas; Åsberg, Signild; Hijazi, Ziad; Wester, Per et al.

Ingår i Circulation, s. 1056-1066, 2022

• DOI för Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study
• Ladda ner fulltext (pdf) av Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study

Is the ESC blowing its own trumpet or should it have a deserved fanfare? The impact and power of registry data

de Belder, Mark A; Deanfield, John; James, Stefan; Oldgren, Jonas

Ingår i European Heart Journal - Quality of Care and Clinical Outcomes, s. 801-803, 2022

• DOI för Is the ESC blowing its own trumpet or should it have a deserved fanfare? The impact and power of registry data

Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation

Hijazi, Ziad; Benz, Alexander P.; Lindbäck, Johan; Alexander, John H. et al.

Ingår i European Heart Journal, s. 208-218, 2022

• DOI för Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation
• Ladda ner fulltext (pdf) av Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation

Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society

Gorog, Diana A; Gue, Ying X; Chao, Tze-Fan; Fauchier, Laurent et al.

Ingår i Europace, s. 1844-1871, 2022

• DOI för Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Piccini, Jonathan P.; Caso, Valeria; Connolly, Stuart J.; Fox, Keith A. A. et al.

Ingår i The Lancet, s. 1383-1390, 2022

• DOI för Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Oral anticoagulation for patients with atrial fibrillation in the ED: RE-LY AF registry analysis.

Mendoza, Pablo A; McIntyre, William F; Belley-Côté, Emilie P; Wang, Jia et al.

Ingår i Journal of Thrombosis and Thrombolysis, s. 74-82, 2022

• DOI för Oral anticoagulation for patients with atrial fibrillation in the ED: RE-LY AF registry analysis.

Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a post hoc analysis of the ATHENA trial

Vamos, Mate; Oldgren, Jonas; Nam, Gi-Byoung; Lip, Gregory Y. H. et al.

Ingår i European Heart Journal - Cardiovascular Pharmacotherapy, s. 363-371, 2022

• DOI för Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a post hoc analysis of the ATHENA trial
• Ladda ner fulltext (pdf) av Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a post hoc analysis of the ATHENA trial

Previous history of hyperthyroidism in emergency department patients with atrial fibrillation does not increase the risk of thromboembolism and death

Chan, Jing Jing; Lim, Swee Han; Tan, Ru San; Wang, Jia et al.

Ingår i Annals of the Academy of Medicine, Singapore, s. 250-252, 2022

• DOI för Previous history of hyperthyroidism in emergency department patients with atrial fibrillation does not increase the risk of thromboembolism and death

Serum Neurofilament Light Chain in Patients With Atrial Fibrillation

Sjölin, Karl; Aulin, Julia; Wallentin, Lars; Eriksson, Niclas et al.

Ingår i Journal of the American Heart Association, 2022

• DOI för Serum Neurofilament Light Chain in Patients With Atrial Fibrillation
• Ladda ner fulltext (pdf) av Serum Neurofilament Light Chain in Patients With Atrial Fibrillation

Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex

Carnicelli, Anthony P.; Hong, Hwanhee; Connolly, Stuart J.; Eikelboom, John et al.

Ingår i Circulation, s. 242-255, 2022

• DOI för Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex

Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model

Aulin, Julia; Hijazi, Ziad; Lindbäck, Johan; Alexander, John H. et al.

Ingår i American Heart Journal, s. 13-24, 2022

• DOI för Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model
• Ladda ner fulltext (pdf) av Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model

Safety and efficacy of double versus triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of NOAC-based randomized clinical trials

Gargiulo, Giuseppe; Cannon, Christopher P; Gibson, C Michael; Goette, Andreas et al.

Ingår i European Heart Journal - Cardiovascular Pharmacotherapy, 2021

• DOI för Safety and efficacy of double versus triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of NOAC-based randomized clinical trials
• Ladda ner fulltext (pdf) av Safety and efficacy of double versus triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of NOAC-based randomized clinical trials

Risk markers of incident atrial fibrillation in patients with coronary heart disease

Tomasdottir, Maria; Held, Claes; Hadziosmanovic, Nermin; Westerbergh, Johan et al.

Ingår i American Heart Journal, s. 92-101, 2021

• DOI för Risk markers of incident atrial fibrillation in patients with coronary heart disease
• Ladda ner fulltext (pdf) av Risk markers of incident atrial fibrillation in patients with coronary heart disease

Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial

Peterson, Benjamin E.; Bhatt, Deepak L.; Steg, Ph Gabriel; Oldgren, Jonas et al.

Ingår i JACC, s. 768-780, 2021

• DOI för Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial
• Ladda ner fulltext (pdf) av Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial

The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE-DUAL PCI subgroup analysis and comparison to other dual antithrombotic therapy trials)

Eccleston, David S.; Kim, Joseph M.; ten Berg, Jurien M.; Steg, P. Gabriel et al.

Ingår i Clinical Cardiology, s. 1002-1010, 2021

• DOI för The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE-DUAL PCI subgroup analysis and comparison to other dual antithrombotic therapy trials)
• Ladda ner fulltext (pdf) av The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE-DUAL PCI subgroup analysis and comparison to other dual antithrombotic therapy trials)

Biomarker-Based Risk Prediction With the ABC-AF Scores in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation

Benz, Alexander P.; Hijazi, Ziad; Lindbäck, Johan; Connolly, Stuart J. et al.

Ingår i Circulation, s. 1863-1873, 2021

• DOI för Biomarker-Based Risk Prediction With the ABC-AF Scores in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation

Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: the 7th AFNET/EHRA Consensus Conference

Fabritz, Larissa; Crijns, Harry J. G. M.; Guasch, Eduard; Goette, Andreas et al.

Ingår i Europace, s. 329-344, 2021

• DOI för Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: the 7th AFNET/EHRA Consensus Conference

Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease

Benz, Alexander P.; Healey, Jeff S.; Chin, Ashley; Commerford, Patrick et al.

Ingår i Cardiovascular Research, s. 295-304, 2021

• DOI för Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease

Screening of biomarkers for prediction of multisite artery disease in patients with recent myocardial infarction

Jönelid, Birgitta; Christersson, Christina; Hedberg, Pär; Leppert, Jerzy et al.

Ingår i Scandinavian Journal of Clinical and Laboratory Investigation, s. 353-360, 2021

• DOI för Screening of biomarkers for prediction of multisite artery disease in patients with recent myocardial infarction
• Ladda ner fulltext (pdf) av Screening of biomarkers for prediction of multisite artery disease in patients with recent myocardial infarction

Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation.

Siegbahn, Agneta; Lindbäck, Johan; Hijazi, Ziad; Åberg, Mikael et al.

Ingår i Journal of Thrombosis and Haemostasis, s. 2726-2737, 2021

• DOI för Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation.
• Ladda ner fulltext (pdf) av Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation.

Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation.

Pol, Tymon; Hijazi, Ziad; Lindbäck, Johan; Oldgren, Jonas et al.

Ingår i Cardiovascular Research, s. 2112-2123, 2021

• DOI för Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation.
• Ladda ner fulltext (pdf) av Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation.

LVS-HARMED Risk Score for Incident Heart Failure in Patients With Atrial Fibrillation Who Present to the Emergency Department: Data from a World-Wide Registry

Johnson, Linda S. B.; Oldgren, Jonas; Barrett, Tyler W.; McNaughton, Candace D. et al.

Ingår i Journal of the American Heart Association, 2021

• DOI för LVS-HARMED Risk Score for Incident Heart Failure in Patients With Atrial Fibrillation Who Present to the Emergency Department: Data from a World-Wide Registry
• Ladda ner fulltext (pdf) av LVS-HARMED Risk Score for Incident Heart Failure in Patients With Atrial Fibrillation Who Present to the Emergency Department: Data from a World-Wide Registry

2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation

Steffel, Jan; Collins, Ronan; Antz, Matthias; Cornu, Pieter et al.

Ingår i Europace, s. 1612-1676, 2021

• DOI för 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation

Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale

Carnicelli, Anthony P; Hong, Hwanhee; Giugliano, Robert P; Connolly, Stuart J et al.

Ingår i American Heart Journal, s. 48-58, 2021

• DOI för Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale

Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST elevation myocardial infarction: results from the randomised RE-DUAL PCI trial.

Zeymer, Uwe; Leiva, Orly; Hohnloser, Stefan H; Steg, Philippe Gabriel et al.

Ingår i EuroIntervention, s. 474-480, 2021

• DOI för Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST elevation myocardial infarction: results from the randomised RE-DUAL PCI trial.

Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo-controlled, exploratory study

Oldgren, Jonas; Laurila, Sanna; Åkerblom, Axel; Latva-Rasku, Aino et al.

Ingår i Diabetes, obesity and metabolism, s. 1505-1517, 2021

• DOI för Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo-controlled, exploratory study

Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention A Subgroup Analysis From the REDUAL PCI Trial

Berry, Natalia C.; Mauri, Laura; Steg, Philippe Gabriel; Bhatt, Deepak L. et al.

Ingår i Circulation. Cardiovascular Interventions, 2020

• DOI för Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention A Subgroup Analysis From the REDUAL PCI Trial
• Ladda ner fulltext (pdf) av Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention A Subgroup Analysis From the REDUAL PCI Trial

Post-resuscitation myocardial dysfunction in out-of-hospital cardiac arrest patients randomized to immediate coronary angiography versus standard of care

Elfwen, Ludvig; Lagedal, Rickard; Rubertsson, Sten; James, Stefan et al.

Ingår i IJC Heart & Vasculature, 2020

• DOI för Post-resuscitation myocardial dysfunction in out-of-hospital cardiac arrest patients randomized to immediate coronary angiography versus standard of care
• Ladda ner fulltext (pdf) av Post-resuscitation myocardial dysfunction in out-of-hospital cardiac arrest patients randomized to immediate coronary angiography versus standard of care

Effects of apixaban compared with warfarin as gain in event-free time: a novel assessment of the results of the ARISTOTLE trial

Berglund, Erik; Wallentin, Lars; Oldgren, Jonas; Renlund, Henrik et al.

Ingår i European Journal of Preventive Cardiology, s. 1311-1319, 2020

• DOI för Effects of apixaban compared with warfarin as gain in event-free time: a novel assessment of the results of the ARISTOTLE trial
• Ladda ner fulltext (pdf) av Effects of apixaban compared with warfarin as gain in event-free time: a novel assessment of the results of the ARISTOTLE trial

Comparison of the Effect of Age (< 75 Versus >= 75) on the Efficacy and Safety of Dual Therapy (Dabigatran plus Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin plus Aspirin plus Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the RE-DUAL PCI Trial)

ten Berg, Jurrien M.; Steg, Philippe Gabriel; Bhatt, Deepak L.; Hohnloser, Stefan H. et al.

Ingår i American Journal of Cardiology, s. 735-743, 2020

• DOI för Comparison of the Effect of Age (< 75 Versus >= 75) on the Efficacy and Safety of Dual Therapy (Dabigatran plus Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin plus Aspirin plus Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the RE-DUAL PCI Trial)
• Ladda ner fulltext (pdf) av Comparison of the Effect of Age (< 75 Versus >= 75) on the Efficacy and Safety of Dual Therapy (Dabigatran plus Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin plus Aspirin plus Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the RE-DUAL PCI Trial)

Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial

Nicolau, Jose C.; Bhatt, Deepak L.; Hohnloser, Stefan H.; Kimura, Takeshi et al.

Ingår i Drugs, s. 995-1005, 2020

• DOI för Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial
• Ladda ner fulltext (pdf) av Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial

Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials

Hijazi, Ziad; Oldgren, Jonas; Lindbäck, Johan; Alexander, John H. et al.

Ingår i JAMA Network Open, 2020

• DOI för Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials

Incidence and outcome of myocardial infarction treated with percutaneous coronary intervention during COVID-19 pandemic

Mohammad, Moman A.; Koul, Sasha; Olivecrona, Göran K.; Götberg, Matthias et al.

Ingår i Heart, s. 1812-1818, 2020

• DOI för Incidence and outcome of myocardial infarction treated with percutaneous coronary intervention during COVID-19 pandemic
• Ladda ner fulltext (pdf) av Incidence and outcome of myocardial infarction treated with percutaneous coronary intervention during COVID-19 pandemic

Weight gain and blood pressure

Sundström, Johan; Lind, Lars; Lampa, Erik; Angerås, Oskar et al.

Ingår i Journal of Hypertension, s. 387-394, 2020

• DOI för Weight gain and blood pressure

Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis

Kloosterman, Marielle; Oldgren, Jonas; Conen, David; Wong, Jorge A. et al.

Ingår i Europace, s. 870-877, 2020

• DOI för Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis

Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation

Hijazi, Ziad; Wallentin, Lars; Lindbäck, Johan; Alexander, John H. et al.

Ingår i Journal of the American Heart Association, 2020

• DOI för Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation
• Ladda ner fulltext (pdf) av Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation

Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post PCI in Patients With Atrial Fibrillation

Steg, Philippe Gabriel; Ducrocq, Gregory; Bhatt, Deepak L; Hohnloser, Stefan H et al.

Ingår i Journal of the American College of Cardiology, s. 238-240, 2020

• DOI för Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post PCI in Patients With Atrial Fibrillation
• Ladda ner fulltext (pdf) av Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post PCI in Patients With Atrial Fibrillation

Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials.

Aulin, Julia; Hijazi, Ziad; Siegbahn, Agneta; Andersson, Ulrika et al.

Ingår i Journal of Thrombosis and Haemostasis, s. 2287-2295, 2020

• DOI för Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials.
• Ladda ner fulltext (pdf) av Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials.

Systematic Coronary Risk Evaluation estimated risk and prevalent subclinical atherosclerosis in coronary and carotid arteries: A population-based cohort analysis from the Swedish Cardiopulmonary Bioimage Study.

Östgren, Carl J; Söderberg, Stefan; Festin, Karin; Angerås, Oskar et al.

Ingår i European Journal of Preventive Cardiology, s. 250-259, 2020

• DOI för Systematic Coronary Risk Evaluation estimated risk and prevalent subclinical atherosclerosis in coronary and carotid arteries: A population-based cohort analysis from the Swedish Cardiopulmonary Bioimage Study.

Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation.

Wallentin, Lars; Lindbäck, Johan; Eriksson, Niclas; Hijazi, Ziad et al.

Ingår i European Heart Journal, s. 4037-4046, 2020

• DOI för Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation.

Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study

McAlister, Finlay A.; Mian, Rajibul; Oldgren, Jonas; Wallentin, Lars et al.

Ingår i PLOS ONE, 2020

• DOI för Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study
• Ladda ner fulltext (pdf) av Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study

Comparison of Dabigatran Plus a P2Y₁₂ Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI.

De Caterina, Raffaele; Procopio, Antonio; Lopez Sendon, José-Luis; Raev, Dimitar et al.

Ingår i American Journal of Medicine, s. 1302-1312, 2020

• DOI för Comparison of Dabigatran Plus a P2Y₁₂ Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI.
• Ladda ner fulltext (pdf) av Comparison of Dabigatran Plus a P2Y₁₂ Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI.

Direct or subacute coronary angiography in out-of-hospital cardiac arrest (DISCO)-An initial pilot-study of a randomized clinical trial

Elfwen, Ludvig; Lagedal, Rickard; Nordberg, Per; James, Stefan et al.

Ingår i Resuscitation, s. 253-261, 2019

• DOI för Direct or subacute coronary angiography in out-of-hospital cardiac arrest (DISCO)-An initial pilot-study of a randomized clinical trial

Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes

Maeng, Michael; Steg, Philippe Gabriel; Bhatt, Deepak L.; Hohnloser, Stefan H. et al.

Ingår i JACC, s. 2346-2355, 2019

• DOI för Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes
• Ladda ner fulltext (pdf) av Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes

Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial

Oldgren, Jonas; Steg, Philippe Gabriel; Hohnloser, Stefan H.; Lip, Gregory Y. H. et al.

Ingår i European Heart Journal, s. 1553-1562, 2019

• DOI för Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial
• Ladda ner fulltext (pdf) av Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial

Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI

Hohnloser, Stefan H.; Steg, Philippe Gabriel; Oldgren, Jonas; Nickenig, Georg et al.

Ingår i JACC, s. 1553-1561, 2019

• DOI för Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI

Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial

Lip, Gregory Y. H.; Mauri, Laura; Montalescot, Gilles; Ozkor, Mick et al.

Ingår i American Heart Journal, s. 13-22, 2019

• DOI för Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial

Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis

ten Berg, Jurrien M.; de Veer, Anne; Oldgren, Jonas; Steg, Philippe Gabriel et al.

Ingår i JACC, s. 2331-2341, 2019

• DOI för Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis

Atrial fibrillation in patients undergoing coronary artery surgery is associated with adverse outcome

Batra, Gorav; Ahlsson, Anders; Lindahl, Bertil; Lindhagen, Lars et al.

Ingår i Upsala Journal of Medical Sciences, s. 70-77, 2019

• DOI för Atrial fibrillation in patients undergoing coronary artery surgery is associated with adverse outcome
• Ladda ner fulltext (pdf) av Atrial fibrillation in patients undergoing coronary artery surgery is associated with adverse outcome

Low Walking Impairment Questionnaire score after a recent myocardial infarction identifies patients with polyvascular disease

Jönelid, Birgitta; Kragsterman, Björn; Berglund, Lars; Andrén, Bertil et al.

Ingår i JRSM Cardiovascular Disease, s. 1-9, 2019

• DOI för Low Walking Impairment Questionnaire score after a recent myocardial infarction identifies patients with polyvascular disease
• Ladda ner fulltext (pdf) av Low Walking Impairment Questionnaire score after a recent myocardial infarction identifies patients with polyvascular disease

Risk of ischemic stroke and utility of CHA₂DS₂-VASc score in women and men with atrial fibrillation

Tomasdottir, Maria; Friberg, Leif; Hijazi, Ziad; Lindbäck, Johan et al.

Ingår i Clinical Cardiology, s. 1003-1009, 2019

• DOI för Risk of ischemic stroke and utility of CHA₂DS₂-VASc score in women and men with atrial fibrillation
• Ladda ner fulltext (pdf) av Risk of ischemic stroke and utility of CHA₂DS₂-VASc score in women and men with atrial fibrillation

Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE-LY Trial

Hijazi, Ziad; Verdecchia, Paolo; Oldgren, Jonas; Andersson, Ulrika et al.

Ingår i Journal of the American Heart Association, 2019

• DOI för Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE-LY Trial
• Ladda ner fulltext (pdf) av Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE-LY Trial

Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation Post-PCI: Time in Therapeutic Range.

Lip, Gregory Y H; Bhatt, Deepak L; Hohnloser, Stefan H; Kimura, Takeshi et al.

Ingår i Journal of the American College of Cardiology, s. 2431-2433, 2019

• DOI för Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation Post-PCI: Time in Therapeutic Range.

Effects of DAPAgliflozin on CARDiac substrate uptake, myocardial efficiency, and myocardial contractile work in type 2 diabetes patients - a description of the DAPACARD study

Åkerblom, Axel; Oldgren, Jonas; Latva-Rasku, Aino; Johansson, Lars et al.

Ingår i Upsala Journal of Medical Sciences, s. 59-64, 2019

• DOI för Effects of DAPAgliflozin on CARDiac substrate uptake, myocardial efficiency, and myocardial contractile work in type 2 diabetes patients - a description of the DAPACARD study
• Ladda ner fulltext (pdf) av Effects of DAPAgliflozin on CARDiac substrate uptake, myocardial efficiency, and myocardial contractile work in type 2 diabetes patients - a description of the DAPACARD study

Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation

Kent, Anthony P.; Brueckmann, Martina; Fraessdorf, Mandy; Connolly, Stuart J. et al.

Ingår i Journal of the American College of Cardiology, s. 255-267, 2018

• DOI för Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation

Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial

Ezekowitz, Michael D.; Pollack, Charles V.; Halperin, Jonathan L.; England, Richard D. et al.

Ingår i European Heart Journal, s. 2959-2971, 2018

• DOI för Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial

Coronary angiography in out-of-hospital cardiac arrest without ST elevation on ECG-Short- and long-term survival

Elfwen, Ludvig; Lagedal, Rickard; James, Stefan K; Jonsson, Martin et al.

Ingår i American Heart Journal, s. 90-95, 2018

• DOI för Coronary angiography in out-of-hospital cardiac arrest without ST elevation on ECG-Short- and long-term survival

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary

Steffel, Jan; Verhamme, Peter; Potpara, Tatjana S.; Albaladejo, Pierre et al.

Ingår i Europace, s. 1231-1242, 2018

• DOI för The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary

Efficacy and safety of dabigatran versus warfarin from the RE-LY trial

Avezum, Alvaro; de Figueiredo Oliveira, Gustavo Bernardes; Diaz, Rafael; Gonzalez Hermosillo, Jesus Antonio et al.

Ingår i Open heart, 2018

• DOI för Efficacy and safety of dabigatran versus warfarin from the RE-LY trial
• Ladda ner fulltext (pdf) av Efficacy and safety of dabigatran versus warfarin from the RE-LY trial

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary

Steffel, Jan; Verhamme, Peter; Potpara, Tatjana S.; Albaladejo, Pierre et al.

Ingår i Kardiologia polska, s. 1283-1298, 2018

• DOI för The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary
• Ladda ner fulltext (pdf) av The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary

Response by Oldgren and Sundström to Letter Regarding Article, "Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events: A Swedish Nationwide, Population-Based Cohort Study"

Oldgren, Jonas; Sundström, Johan

Ingår i Circulation, s. 2313-2313, 2018

• DOI för Response by Oldgren and Sundström to Letter Regarding Article, "Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events: A Swedish Nationwide, Population-Based Cohort Study"

A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score

Hijazi, Ziad; Oldgren, Jonas; Lindbäck, Johan; Alexander, John H. et al.

Ingår i European Heart Journal, s. 477-485, 2018

• DOI för A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score
• Ladda ner fulltext (pdf) av A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

Steffel, Jan; Verhamme, Peter; Potpara, Tatjana S.; Albaladejo, Pierre et al.

Ingår i European Heart Journal, s. 1330-1393, 2018

• DOI för The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

Design of DISCO-Direct or Subacute Coronary Angiography in Out-of-Hospital Cardiac Arrest study

Lagedal, Rickard; Elfwén, Ludvig; James, Stefan K; Oldgren, Jonas et al.

Ingår i American Heart Journal, s. 53-61, 2018

• DOI för Design of DISCO-Direct or Subacute Coronary Angiography in Out-of-Hospital Cardiac Arrest study

New Biomarkers Associated With Cardiovascular Death In Patients With Atrial Fibrillation Using Multimarker Screening: Insights From The Aristotle Trial

Pol, Tymon; Hijazi, Ziad; Lindbäck, Johan; Oldgren, Jonas et al.

Ingår i Journal of the American College of Cardiology, s. 330-330, 2018

• DOI för New Biomarkers Associated With Cardiovascular Death In Patients With Atrial Fibrillation Using Multimarker Screening: Insights From The Aristotle Trial

Novel Prognostic Biomarkers For Ischemic Stroke In Patients With Atrial Fibrillation Using Multimarker Screening: Insights From The Aristotle Trial

Hijazi, Ziad; Pol, Tymon; Oldgren, Jonas; Lindbäck, Johan et al.

Ingår i Journal of the American College of Cardiology, s. 506-506, 2018

Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis

Hijazi, Ziad; Hohnloser, Stefan H.; Oldgren, Jonas; Andersson, Ulrika et al.

Ingår i American Heart Journal, s. 169-177, 2018

• DOI för Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis

Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation: The authors reply

Cannon, Christopher P.; Lip, Gregory Y. H.; Oldgren, Jonas

Ingår i New England Journal of Medicine, s. 485-486, 2018

• DOI för Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation: The authors reply

Förstahandsvalet som strokeprevention vid förmaksflimmer: Randomiserade studier med >70 000 patienter har visat på fördelarna med NOAK

Oldgren, Jonas

Ingår i Läkartidningen, 2018

Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference.

Kotecha, Dipak; Breithardt, Günter; Camm, A John; Lip, Gregory Y H et al.

Ingår i Europace, s. 395-407, 2018

• DOI för Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference.
• Ladda ner fulltext (pdf) av Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference.

Antithrombotic therapy after myocardial infarction in patients with atrial fibrillation undergoing percutaneous coronary intervention

Batra, Gorav; Friberg, Leif; Erlinge, David; James, Stefan K et al.

Ingår i European Heart Journal - Cardiovascular Pharmacotherapy, s. 36-45, 2018

• DOI för Antithrombotic therapy after myocardial infarction in patients with atrial fibrillation undergoing percutaneous coronary intervention

Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial

Proietti, M.; Hijazi, Ziad; Andersson, Ulrika; Connolly, S. J. et al.

Ingår i Journal of Internal Medicine, s. 282-292, 2018

• DOI för Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial

Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events: A Swedish Nationwide, Population-Based Cohort Study

Sundström, Johan; Hedberg, Jakob; Thuresson, Marcus; Aarskog, Pernilla et al.

Ingår i Circulation, s. 1183-1192, 2017

• DOI för Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events: A Swedish Nationwide, Population-Based Cohort Study

Subgroup Analysis From the RE-DUAL PCI Trial: Dual Antithrombotic Therapy With Dabigatran in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Oldgren, Jonas; Steg, Philippe-Gabriel; Hohnloser, Stefan H.; Lip, Gregory Y. et al.

Ingår i Circulation, 2017

2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS

Kirchhof, Paulus; Benussi, Stefano; Kotecha, Dipak; Ahlsson, Anders et al.

Ingår i Revista espanola de cardiologia (English ed.), 2017

• DOI för 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS

Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial

Hijazi, Ziad; Oldgren, Jonas; Andersson, Ulrika; Connolly, Stuart J et al.

Ingår i American Heart Journal, s. 94-103, 2017

• DOI för Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial

Timing of oral anticoagulant therapy in acute ischemic stroke with atrial fibrillation: study protocol for a registry-based randomised controlled trial

Åsberg, Signild; Hijazi, Ziad; Norrving, Bo; Terént, Andreas et al.

Ingår i Trials, 2017

• DOI för Timing of oral anticoagulant therapy in acute ischemic stroke with atrial fibrillation: study protocol for a registry-based randomised controlled trial
• Ladda ner fulltext (pdf) av Timing of oral anticoagulant therapy in acute ischemic stroke with atrial fibrillation: study protocol for a registry-based randomised controlled trial

Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions

Lund, Lars H; Oldgren, Jonas; James, Stefan

Ingår i Current Heart Failure Reports, s. 59-70, 2017

• DOI för Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions
• Ladda ner fulltext (pdf) av Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions

Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation

Friberg, Leif; Oldgren, Jonas

Ingår i Open heart, 2017

• DOI för Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation
• Ladda ner fulltext (pdf) av Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation

Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial

Essebag, Vidal; Proietti, Riccardo; Birnie, David H.; Wang, Jia et al.

Ingår i Europace, s. 1630-1636, 2017

• DOI för Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial

Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary

Heidbuchel, Hein; Verhamme, Peter; Alings, Marco; Antz, Matthias et al.

Ingår i European Heart Journal, s. 2137-2149, 2017

• DOI för Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary

Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time

Hijazi, Ziad; Lindahl, Bertil; Oldgren, Jonas; Andersson, Ulrika et al.

Ingår i Journal of the American Heart Association, 2017

• DOI för Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time

Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study

Sjögren, Vilhelm; Byström, Björn; Renlund, Henrik; Svensson, Peter J. et al.

Ingår i PLOS ONE, 2017

• DOI för Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study

Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation

Cannon, Christopher P.; Bhatt, Deepak L.; Oldgren, Jonas; Lip, Gregory Y. H. et al.

Ingår i New England Journal of Medicine, s. 1513-1524, 2017

• DOI för Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation

The utility of coagulation activity for prediction of risk of mortality and cardiovascular events in guideline-treated myocardial infarction patients

Christersson, Christina; Lindahl, Bertil; Berglund, Lars; Siegbahn, Agneta et al.

Ingår i Upsala Journal of Medical Sciences, s. 224-233, 2017

• DOI för The utility of coagulation activity for prediction of risk of mortality and cardiovascular events in guideline-treated myocardial infarction patients
• Ladda ner fulltext (pdf) av The utility of coagulation activity for prediction of risk of mortality and cardiovascular events in guideline-treated myocardial infarction patients

Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are associated with improved outcome but do not prevent new-onset atrial fibrillation after acute myocardial infarction

Batra, Gorav; Lindhagen, Lars; Andell, Pontus; Erlinge, David et al.

Ingår i Journal of the American Heart Association, 2017

• DOI för Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are associated with improved outcome but do not prevent new-onset atrial fibrillation after acute myocardial infarction
• Ladda ner fulltext (pdf) av Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are associated with improved outcome but do not prevent new-onset atrial fibrillation after acute myocardial infarction

Risk of stroke in women and men with atrial fibrillation and only one additional CHA2DS2-VASC risk factor

Tomasdottir, Maria; Friberg, Leif; Hijazi, Ziad; Lindbäck, Johan et al.

Ingår i Journal of the American College of Cardiology, s. 327-327, 2017

• DOI för Risk of stroke in women and men with atrial fibrillation and only one additional CHA2DS2-VASC risk factor

Effects of dabigatran according to age in atrial fibrillation

Lauw, Mandy N.; Eikelboom, John W.; Coppens, Michiel; Wallentin, Lars et al.

Ingår i Heart, s. 1015-1023, 2017

• DOI för Effects of dabigatran according to age in atrial fibrillation

Dabigatran etexilate and reduction in serum apolipoprotein B

Joseph, Philip; Pare, Guillaume; Wallentin, Lars; Connolly, Stuart et al.

Ingår i Heart, s. 57-62, 2016

• DOI för Dabigatran etexilate and reduction in serum apolipoprotein B

Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial

Ezekowitz, Michael D.; Pollack, Charles V.; Sanders, Paul; Halperin, Jonathan L. et al.

Ingår i American Heart Journal, s. 59-68, 2016

• DOI för Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial
• Ladda ner fulltext (pdf) av Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial

Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation

Ezekowitz, Michael D.; Eikelboom, John; Oldgren, Jonas; Reilly, Paul A. et al.

Ingår i Europace, s. 973-978, 2016

• DOI för Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation

Efficacy And Safety Of Non-Vitamin K Oral Anticoagulants (NOAC) Compared With Warfarin At Its Best In Patients With Atrial Fibrillation

Oldgren, Jonas; Friberg, L.

Ingår i International Journal of Stroke, s. 46-46, 2016

Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers are associated with improved outcome but do not prevent new-onset atrial fibrillation after acute myocardial infarction

Batra, Gorav; Andell, P.; Erlinge, D.; James, Stefan et al.

Ingår i European Heart Journal, s. 1387-1387, 2016

• DOI för Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers are associated with improved outcome but do not prevent new-onset atrial fibrillation after acute myocardial infarction

Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting

Cannon, Christopher P.; Gropper, Savion; Bhatt, Deepak L.; Ellis, Stephen G. et al.

Ingår i Clinical Cardiology, s. 555-564, 2016

• DOI för Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting
• Ladda ner fulltext (pdf) av Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting

Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation

Oldgren, Jonas; Hijazi, Ziad; Lindbäck, Johan; Alexander, John H et al.

Ingår i Circulation, s. 1697-1707, 2016

• DOI för Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation

Cardiac biomarkers and left ventricular hypertrophy in relation to outcomes in patients with atrial fibrillation: experiences from the RELY trial

Hijazi, Ziad; Verdecchia, P.; Oldgren, Jonas; Andersson, Ulrika et al.

Ingår i EUROPEAN HEART JOURNAL, s. 47-47, 2016

External Validation Of The Biomarker-Based ABC-Bleeding Risk Score For Atrial Fibrillation

Hijazi, Ziad; Oldgren, Jonas; Lindbäck, Johan; Alexander, John et al.

Ingår i Journal of the American College of Cardiology, s. 893-893, 2016

D-dimer and factor VIIa in atrial fibrillation: prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy

Siegbahn, Agneta; Oldgren, Jonas; Andersson, Ulrika; Ezekowitz, Michael D et al.

Ingår i Thrombosis and Haemostasis, s. 921-930, 2016

• DOI för D-dimer and factor VIIa in atrial fibrillation: prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy

External Validation Of The Biomarker-Based ABC-Stroke Risk Score For Atrial Fibrillation

Oldgren, Jonas; Hijazi, Ziad; Lindbäck, Johan; Alexander, John et al.

Ingår i Journal of the American College of Cardiology, s. 879-879, 2016

A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference

Kirchhof, Paulus; Breithardt, Guenter; Bax, Jeroen; Benninger, Gerlinde et al.

Ingår i Europace, s. 37-50, 2016

• DOI för A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference

The ABC risk score for patients with atrial fibrillation Reply

Hijazi, Ziad; Oldgren, Jonas; Lindbäck, Johan; Siegbahn, Agneta et al.

Ingår i The Lancet, s. 1980-1981, 2016

All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcome

Batra, Gorav; Svennblad, Bodil; Held, Claes; Jernberg, Tomas et al.

Ingår i Heart, s. 926-933, 2016

• DOI för All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcome

Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy

Eriksson, Niclas; Wallentin, Lars; Berglund, Lars; Axelsson, Tomas et al.

Ingår i Pharmacogenomics (London), s. 1425-1439, 2016

• DOI för Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy
• Ladda ner fulltext (pdf) av Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy

The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation

Hijazi, Ziad; Lindbäck, Johan; Alexander, John H.; Hanna, Michael et al.

Ingår i European Heart Journal, s. 1582-1590, 2016

• DOI för The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation

The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study

Hijazi, Ziad; Oldgren, Jonas; Lindbäck, Johan; Alexander, John H. et al.

Ingår i The Lancet, s. 2302-2311, 2016

• DOI för The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study

Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation

Heidbuchel, Hein; Verhamme, Peter; Alings, Marco; Antz, Matthias et al.

Ingår i Europace, s. 1467-1507, 2015

• DOI för Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation

Clinical outcomes of atrial fibrillation patients receiving NSAIDs in the RE-LY trial

Ezekowitz, M. D.; Connolly, S. J.; Fraessdorf, M.; Brueckmann, M. et al.

Ingår i European Heart Journal, s. 862-862, 2015

Outcome In Relation To Antithrombotic Therapy After Myocardial Infarction And Percutaneous Coronary Intervention In Patients With Atrial Fibrillation

Batra, Gorav; Friberg, Leif; Erlinge, David; James, Stefan et al.

Ingår i Journal of the American College of Cardiology, 2015

• DOI för Outcome In Relation To Antithrombotic Therapy After Myocardial Infarction And Percutaneous Coronary Intervention In Patients With Atrial Fibrillation

Antithrombotic Medication And Outcomes After Myocardial Infarction In Patients With Atrial Fibrillation Not Undergoing Percutaneous Coronary Intervention

Batra, Gorav; Friberg, Leif; Erlinge, David; James, Stefan et al.

Ingår i Journal of the American College of Cardiology, 2015

• DOI för Antithrombotic Medication And Outcomes After Myocardial Infarction In Patients With Atrial Fibrillation Not Undergoing Percutaneous Coronary Intervention

Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction

Szummer, K; Oldgren, Jonas; Lindhagen, Lars; Carrero, J J et al.

Ingår i Journal of the American Medical Association (JAMA), s. 707-716, 2015

• DOI för Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction

Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE-LY trial

Westenbrink, B. D.; Alings, M.; Connolly, S. J.; Eikelboom, J. et al.

Ingår i Journal of Thrombosis and Haemostasis, s. 699-707, 2015

• DOI för Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE-LY trial

Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure: Substudy of the RE-LY trial

Douketis, J D; Healey, J S; Brueckmann, M; Eikelboom, J W et al.

Ingår i Thrombosis and Haemostasis, s. 625-632, 2015

• DOI för Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure: Substudy of the RE-LY trial

Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial

Brambatti, Michela; Darius, Harald; Oldgren, Jonas; Clemens, Andreas et al.

Ingår i International Journal of Cardiology, s. 127-131, 2015

• DOI för Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial

Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation

Aulin, Julia; Siegbahn, Agneta; Hijazi, Ziad; Ezekowitz, Michael D. et al.

Ingår i American Heart Journal, s. 1151-1160, 2015

• DOI för Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation

Importance of Persistent Elevation of Cardiac Biomarkers in Atrial Fibrillation: a RE-LY Substudy

Hijazi, Ziad; Oldgren, Jonas; Andersson, Ulrika; Connolly, Stuart J. et al.

Ingår i Heart, s. 1193-1200, 2014

• DOI för Importance of Persistent Elevation of Cardiac Biomarkers in Atrial Fibrillation: a RE-LY Substudy

Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis

Hijazi, Ziad; Hohnloser, Stefan H.; Oldgren, Jonas; Andersson, Ulrika et al.

Ingår i Circulation, s. 961-970, 2014

• DOI för Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis

Response to Letter Regarding Article, "Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial Analysis"

Hijazi, Ziad; Hohnloser, Stefan H.; Oldgren, Jonas; Andersson, Ulrika et al.

Ingår i Circulation, 2014

• DOI för Response to Letter Regarding Article, "Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial Analysis"

Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries The RE-LY Atrial Fibrillation Registry

Oldgren, Jonas; Healey, Jeff S.; Ezekowitz, Michael; Commerford, Patrick et al.

Ingår i Circulation, s. 1568-1576, 2014

• DOI för Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries The RE-LY Atrial Fibrillation Registry

Authors' response: from monitoring to vigilance about patient adherence to new oral anticoagulants

Heidbuchel, Hein; Verhamme, Peter; Alings, Marco; Antz, Matthias et al.

Ingår i Europace, s. 149-150, 2014

• DOI för Authors' response: from monitoring to vigilance about patient adherence to new oral anticoagulants

Author reply: To PMID 23625942

Heidbuchel, Hein; Verhamme, Peter; Alings, Marco; Antz, Matthias et al.

Ingår i Europace, s. 151-152, 2014

• DOI för Author reply: To PMID 23625942

Biomarkers in atrial fibrillation: a clinical review

Hijazi, Ziad; Oldgren, Jonas; Siegbahn, Agneta; Granger, Christopher B et al.

Ingår i European Heart Journal, s. 1475-1480, 2013

• DOI för Biomarkers in atrial fibrillation: a clinical review

EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary

Heidbuchel, Hein; Verhamme, Peter; Alings, Marco; Antz, Matthias et al.

Ingår i European Heart Journal, s. 2094-2106, 2013

• DOI för EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary

Low-dose acetylsalicylic acid and gastrointestinal ulcers or bleeding - a cohort study of the effects of proton pump inhibitor use patterns

Hedberg, Jakob; Sundström, Johan; Thuresson, M.; Aarskog, P. et al.

Ingår i Journal of Internal Medicine, s. 371-380, 2013

• DOI för Low-dose acetylsalicylic acid and gastrointestinal ulcers or bleeding - a cohort study of the effects of proton pump inhibitor use patterns

The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study

Connolly, Stuart J.; Wallentin, Lars; Ezekowitz, Michael D.; Eikelboom, John et al.

Ingår i Circulation, s. 237-243, 2013

• DOI för The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study

"Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial" Response

Healey, Jeff S.; Eikelboom, John; Yang, Sean; Themeles, Ellison et al.

Ingår i Circulation, 2013

• DOI för "Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial" Response

New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis

Oldgren, Jonas; Wallentin, Lars; Alexander, John H; James, Stefan et al.

Ingår i European Heart Journal, s. 1670-1680, 2013

• DOI för New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis
• Ladda ner fulltext (pdf) av New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis

Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding

Paré, Guillaume; Eriksson, Niclas; Lehr, Thorsten; Connolly, Stuart et al.

Ingår i Circulation, s. 1404, 2013

• DOI för Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding

Response to Letter Regarding Article, "Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy"

Hijazi, Ziad; Oldgren, Jonas; Wallentin, Lars; Andersson, Ulrika et al.

Ingår i Circulation, 2013

• DOI för Response to Letter Regarding Article, "Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy"

Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden

Davidson, Thomas; Husberg, Magnus; Janzon, Magnus; Oldgren, Jonas et al.

Ingår i European Heart Journal, s. 177-183, 2013

• DOI för Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden

European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation

Heidbuchel, Hein; Verhamme, Peter; Alings, Marco; Antz, Matthias et al.

Ingår i Europace, s. 625-651, 2013

• DOI för European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation

Balancing the Benefits and Risks of 2 Doses of Dabigatran Compared With Warfarin in Atrial Fibrillation

Eikelboom, John W.; Connolly, Stuart J.; Hart, Robert G.; Wallentin, Lars et al.

Ingår i Journal of the American College of Cardiology, s. 900-908, 2013

• DOI för Balancing the Benefits and Risks of 2 Doses of Dabigatran Compared With Warfarin in Atrial Fibrillation

Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY®) Trial

Dans, Antonio L; Connolly, Stuart J; Wallentin, Lars; Yang, Sean et al.

Ingår i Circulation, s. 634-640, 2013

• DOI för Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY®) Trial

Response to letters regarding article: “Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial"

Healey, Jeff S; Eikelboom, John; Yang, Sean; Themeles, Ellison et al.

Ingår i Circulation, 2013

• DOI för Response to letters regarding article: “Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial"

Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy

Hijazi, Ziad; Oldgren, Jonas; Andersson, Ulrika; Connolly, Stuart J. et al.

Ingår i Circulation, s. 1605-1616, 2012

• DOI för Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy

Reply to Letters Regarding Article: "Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation : An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial"

Eikelboom, John W.; Connolly, Stuart J.; Healey, Jeff S.; Yang, Sean et al.

Ingår i Circulation, 2012

• DOI för Reply to Letters Regarding Article: "Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation : An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial"

Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial

Hohnloser, Stefan H.; Oldgren, Jonas; Yang, Sean; Wallentin, Lars et al.

Ingår i Circulation, s. 669-676, 2012

• DOI för Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial

Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial

Healey, Jeff S.; Eikelboom, John; Douketis, James; Wallentin, Lars et al.

Ingår i Circulation, s. 343-348, 2012

• DOI för Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial

Randomized Comparison of the Effects of Two Doses of Dabigatran Etexilate on Clinical Outcomes Over 4.3 Years: Results of the Rely-Able Double-Blind Randomized Trial

Connolly, Stuart J.; Reilly, Paul A.; Pogue, Janice; Eikelboom, John et al.

Ingår i Circulation, s. 2793-2793, 2012

Dabigatran Versus Warfarin in Patients With Atrial Fibrillation An Analysis of Patients Undergoing Cardioversion

Nagarakanti, Rangadham; Ezekowitz, Michael D.; Oldgren, Jonas; Yang, Sean et al.

Ingår i Circulation, s. 131-136, 2011

• DOI för Dabigatran Versus Warfarin in Patients With Atrial Fibrillation An Analysis of Patients Undergoing Cardioversion

Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial

Eikelboom, John W.; Wallentin, Lars; Connolly, Stuart J.; Ezekowitz, Mike et al.

Ingår i Circulation, s. 2363-2372, 2011

• DOI för Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial

Treatment with an Oral Direct Thrombin Inhibitor Decreases Platelet Activity but Increases Markers of Inflammation in Patients with Myocardial Infarction.

Christersson, Christina; Oldgren, Jonas; Wallentin, Lars; Siegbahn, Agneta

Ingår i Journal of Internal Medicine, s. 215-223, 2011

• DOI för Treatment with an Oral Direct Thrombin Inhibitor Decreases Platelet Activity but Increases Markers of Inflammation in Patients with Myocardial Infarction.

Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS(2) Score: A Subgroup Analysis of the RE-LY Trial

Oldgren, Jonas; Alings, Marco; Darius, Harald; Diener, Hans-Christoph et al.

Ingår i Annals of Internal Medicine, s. 660-667, 2011

Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial

Oldgren, Jonas; Budaj, Andrzej; Granger, Christopher B.; Khder, Yasser et al.

Ingår i European Heart Journal, s. 2781-2789, 2011

• DOI för Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial

Myeloperoxidase is not useful for the early assessment of patients with chest pain

Eggers, Kai M.; Dellborg, Mikael; Johnston, Nina; Oldgren, Jonas et al.

Ingår i Clinical Biochemistry, s. 240-245, 2010

• DOI för Myeloperoxidase is not useful for the early assessment of patients with chest pain

Fibrinolytic therapy and bleeding complications: risk predictors from RIKS-HIA

Oldgren, Jonas; Wernroth, Lisa; Stenestrand, Ulf

Ingår i Heart, s. 1451-1457, 2010

• DOI för Fibrinolytic therapy and bleeding complications: risk predictors from RIKS-HIA

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial

Wallentin, Lars; Yusuf, Salim; Ezekowitz, Michael D.; Alings, Marco et al.

Ingår i The Lancet, s. 975-983, 2010

• DOI för Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial

Long-Term Results Following Switch From Abciximab to Eptifibatide During Percutaneous Coronary Intervention

Koutouzis, Michael; Lagerqvist, Bo; Oldgren, Jonas; Åkerblom, Axel et al.

Ingår i Clinical Cardiology, s. 686-692, 2010

• DOI för Long-Term Results Following Switch From Abciximab to Eptifibatide During Percutaneous Coronary Intervention

Eptifibatide Is Noninferior to Abciximab in Primary Percutaneous Coronary Intervention Results From the SCAAR (Swedish Coronary Angiography and Angioplasty Registry)

Åkerblom, Axel; James, Stefan K.; Koutouzis, Michail; Lagerqvist, Bo et al.

Ingår i Journal of the American College of Cardiology, s. 470-475, 2010

• DOI för Eptifibatide Is Noninferior to Abciximab in Primary Percutaneous Coronary Intervention Results From the SCAAR (Swedish Coronary Angiography and Angioplasty Registry)

Lipoprotein-associated phospholipase A₂ and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies

Thompson, Alexander; Gao, Pei; Orfei, Lia; Watson, Sarah et al.

Ingår i The Lancet, s. 1536-1544, 2010

• DOI för Lipoprotein-associated phospholipase A₂ and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies

Platelet inhibition assessed with VerifyNow, flow cytometry and PlateletMapping in patients undergoing heart surgery

Alström, Ulrica; Granath, Fredrik; Oldgren, Jonas; Ståhle, Elisabeth et al.

Ingår i Thrombosis Research, s. 572-577, 2009

• DOI för Platelet inhibition assessed with VerifyNow, flow cytometry and PlateletMapping in patients undergoing heart surgery

Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran

Ezekowitz, Michael D.; Connolly, Stuart; Parekh, Amit; Reilly, Paul A. et al.

Ingår i American Heart Journal, s. 805-810, 2009

• DOI för Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran

Fortfarande stor anledning till entusiasm över ett nytt strokeförebyggande läkemedel

Oldgren, Jonas

Ingår i Läkartidningen, s. 3020-3021, 2009

Dabigatran versus warfarin in patients with atrial fibrillation

Connolly, Stuart J.; Ezekowitz, Michael D.; Yusuf, Salim; Eikelboom, John et al.

Ingår i New England Journal of Medicine, s. 1139-1151, 2009

• DOI för Dabigatran versus warfarin in patients with atrial fibrillation

Pathophysiologic mechanisms of persistent cardiac troponin I elevation in stabilized patients after an episode of acute coronary syndrome

Eggers, Kai M.; Lagerqvist, Bo; Oldgren, Jonas; Venge, Per et al.

Ingår i American Heart Journal, s. 588-594, 2008

• DOI för Pathophysiologic mechanisms of persistent cardiac troponin I elevation in stabilized patients after an episode of acute coronary syndrome

Risk prediction in chest pain patients by biochemical markers including estimates of renal function

Eggers, Kai; Dellborg, Mikael; Oldgren, Jonas; Swahn, Eva et al.

Ingår i International Journal of Cardiology, s. 207-213, 2008

• DOI för Risk prediction in chest pain patients by biochemical markers including estimates of renal function

The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial

Peters, Ron J. G.; Joyner, Campbell; Bassand, Jean-Pierre; Afzal, Rizwan et al.

Ingår i European Heart Journal, s. 324-331, 2008

• DOI för The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial

Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial

Tangelder, Marco J. D.; Frison, Lars; Weaver, Douglas; Wilcox, Robbert G. et al.

Ingår i American Heart Journal, s. 382-7, 2008

• DOI för Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial

Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment

Oldgren, Jonas; Wallentin, Lars; Afzal, Rizwan; Bassand, Jean-Pierre et al.

Ingår i European Heart Journal, s. 315-23, 2008

• DOI för Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment

Xa inhibition and coagulation activity: the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals

Oldgren, Jonas; Johnston, Nina; Siegbahn, Agneta

Ingår i American Heart Journal, s. 4930, 2008

• DOI för Xa inhibition and coagulation activity: the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals

Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischemic events: Observations from the ESTEEM trial

Christersson, Christina; Oldgren, Jonas; Bylock, Anders; Siegbahn, Agneta et al.

Ingår i European Heart Journal, s. 692-698, 2007

• DOI för Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischemic events: Observations from the ESTEEM trial

Artificial neural network algorithms for early diagnosis of acute myocardial infarction and prediction of infarct size in chest pain patients

Eggers, Kai; Ellenius, Johan; Dellborg, Mikael; Groth, Torgny et al.

Ingår i International Journal of Cardiology, s. 366-374, 2007

• DOI för Artificial neural network algorithms for early diagnosis of acute myocardial infarction and prediction of infarct size in chest pain patients

Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients

Oldgren, Jonas; James, Stefan; Siegbahn, Agneta; Wallentin, Lars

Ingår i European Heart Journal, s. 699-704, 2007

• DOI för Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients

Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM: Reply

Christersson, Christina; Oldgren, Jonas; Bylock, Anders; Siegbahn, Agneta et al.

Ingår i European Heart Journal, s. 1783-1783, 2007

• DOI för Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM: Reply

The platelet inhibiting effect of a clopidogrel bolus dose in patients on long-term acetylsalicylic acid treatment

Alström, Ulrica; Tydén, Hans; Oldgren, Jonas; Siegbahn, Agneta et al.

Ingår i Thrombosis Research, s. 353-359, 2007

• DOI för The platelet inhibiting effect of a clopidogrel bolus dose in patients on long-term acetylsalicylic acid treatment

An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease

James, Stefan K; Oldgren, Jonas; Lindbäck, Johan; Johnston, Nina et al.

Ingår i American Heart Journal, s. 619-626, 2005

• DOI för An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease

Risk prediction in patients with chest pain: early assessment by the combination of troponin I results and electrocardiographic findings

Eggers, Kai M.; Oldgren, Jonas; Nordenskjöld, Anna; Lindahl, Bertil

Ingår i Coronary Artery Disease, s. 181-9, 2005

Combining different biochemical markers of myocardial ischemia does not improve risk stratification in chest pain patients compared to troponin I alone

Eggers, Kai M.; Oldgren, Jonas; Nordensköld, Anna; Lindahl, Bertil

Ingår i Coronary Artery Disease, s. 315-9, 2005

Influence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery disease

Oldgren, Jonas; Fellenius, C.; Boman, K.; Jansson, J-H. et al.

Ingår i Journal of Internal Medicine, s. 420-7, 2005

• DOI för Influence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery disease

Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction

Christersson, Christina; Oldgren, Jonas; Bylock, A.; Wallentin, Lars et al.

Ingår i Journal of Thrombosis and Haemostasis, s. 2245-53, 2005

• DOI för Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction

Combining different biochemical markers of myocardial ischemia does not improve risk stratification in chest pain patients compared to troponin I alone.

Eggers, Kai; Oldgren, Jonas; Nordenskjöld, Anna; Lindahl, Bertil

Ingår i Coronary Artery Disease, s. 315-319, 2005

Analytical performance of a new point of care instrument for measurement of cardiac markers - an evaluation under clinical conditions

Eggers, K M; Oldgren, J; Berg, A; Lindahl, B

Ingår i Point of Care, 2005

Adrenaline administration during cardiopulmonary resuscitation: poor adherence to clinical guidelines

Johansson, Jakob; Hammerby, Rutger; Oldgren, Jonas; Rubertsson, Sten et al.

Ingår i Acta Anaesthesiologica Scandinavica, s. 909-913, 2004

• DOI för Adrenaline administration during cardiopulmonary resuscitation: poor adherence to clinical guidelines

Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to troponin I for exclusion of myocardial infarction

Eggers, Kai; Oldgren, Jonas; Nordenskjöld, Anna; Lindahl, Bertil

Ingår i American Heart Journal, s. 574-581, 2004

• DOI för Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to troponin I for exclusion of myocardial infarction

Diagnostic value of serial measurement of cardiac markers in patients with chest pain.: Limited value of adding myoglobin to troponin I for exclusion of myocardial infarction.

Eggers, Kai; Oldgren, Jonas; Nordenskjöld, Anna; Lindahl, Bertil

Ingår i American Heart Journal, s. 574-581, 2004

Myocardial damage, coagulation activity and the response to thrombin inhibition in unstable coronary artery disease.

Oldgren, Jonas; Siegbahn, Agneta; Grip, Lars; Linder, Rikard et al.

Ingår i Thromb Haemost, s. 381-7, 2004

Myocardial Damage, Inflammation and Thrombin Inhibition in Unstable Coronary Artery Disease

Oldgren, Jonas; Wallentin, Lars; Grip, L; Linder, R et al.

Ingår i European Heart Journal, s. 86-93, 2003

• DOI för Myocardial Damage, Inflammation and Thrombin Inhibition in Unstable Coronary Artery Disease

Biomarkers in addition to clinical characteristics for prediction of peripheral artery disease in patients with recent myocardial infarction

Jönelid, Birgitta; Christersson, Christina; Hedberg, P; Leppert, Jerzy et al.

Large simple randomized controlled trials – from drugs to medical devices: lessons from recent experience

Buccheri, Sergio; James, Stefan; Mafham, Marion; Landray, Martin et al.

Ingår i Trials, 2025

• DOI för Large simple randomized controlled trials – from drugs to medical devices: lessons from recent experience
• Ladda ner fulltext (pdf) av Large simple randomized controlled trials – from drugs to medical devices: lessons from recent experience

Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia-Pacific Expert Consensus Paper

Gorog, Diana A; Gue, Ying X; Chao, Tze-Fan; Fauchier, Laurent et al.

Ingår i Thrombosis and Haemostasis, s. 1625-1652, 2022

• DOI för Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia-Pacific Expert Consensus Paper

Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review andmeta-analysis of randomized clinical trials

Golwala, Harsh B.; Cannon, Christopher P.; Steg, Ph. Gabriel; Doros, Gheorghe et al.

Ingår i European Heart Journal, s. 1726-+, 2018

• DOI för Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review andmeta-analysis of randomized clinical trials
• Ladda ner fulltext (pdf) av Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review andmeta-analysis of randomized clinical trials

Effects of sauna bath on heart failure: A systematic review and meta-analysis

Källström, Miikka; Soveri, Inga; Oldgren, Jonas; Laukkanen, Jari et al.

Ingår i Clinical Cardiology, s. 1491-1501, 2018

• DOI för Effects of sauna bath on heart failure: A systematic review and meta-analysis
• Ladda ner fulltext (pdf) av Effects of sauna bath on heart failure: A systematic review and meta-analysis

Application of Biomarkers for Risk Stratification in Patients with Atrial Fibrillation

Hijazi, Ziad; Oldgren, Jonas; Siegbahn, Agneta; Wallentin, Lars

Ingår i Clinical Chemistry, s. 152-164, 2017

• DOI för Application of Biomarkers for Risk Stratification in Patients with Atrial Fibrillation

Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial

Douketis, James D.; Healey, Jeff S.; Brueckmann, Martina; Fraessdorf, Mandy et al.

Ingår i Thrombosis Research, s. 77-81, 2016

• DOI för Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial

Stora studier av NOAK visar på gott och säkert strokeskydd

Hijazi, Ziad; Oldgren, Jonas

Ingår i Läkartidningen, 2015

Combination of a new oral anticoagulant, aspirin and clopidogrel after acute coronary syndrome: new therapeutic standard?

Rubboli, Andrea; Oldgren, Jonas; Marin, Francisco; Lip, Gregory

Ingår i Internal and Emergency Medicine, s. 673-680, 2013

• DOI för Combination of a new oral anticoagulant, aspirin and clopidogrel after acute coronary syndrome: new therapeutic standard?

Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation

Sinnaeve, P. R.; Brueckmann, M.; Clemens, A.; Oldgren, Jonas et al.

Ingår i Journal of Internal Medicine, s. 15-24, 2012

• DOI för Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation

Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases

Ballantyne, C.; Cushman, M.; Psaty, B.; Furberg, C. et al.

Ingår i European Journal of Cardiovascular Prevention & Rehabilitation, s. 3-11, 2007

• DOI för Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases

Growth differentiation factor 15 is an independent marker of risk of major bleeding in atrial fibrillation: insights from the RE-LY trial

Hijazi, Ziad; Oldgren, Jonas; Andersson, Ulrika; Connolly, S. J. et al.

s. 429-429, 2016

Biochemical biomarkers associated with peripheral artery disease contribute to prediction of outcome during long-term follow up after myocardial infarction

Jönelid, Birgitta; Lindahl, Bertil; Johnston, Nina; Lindhagen, Lars et al.

Screening of plasma biomarkers for heart failure hospitalizations and heart failure subtype in patients with atrial fibrillation

Pol, Tymon; Lindbäck, Johan; Oldgren, Jonas; Alexander, John H. et al.